Eo. Ngo et al., INDUCTION OF P53 BY THE CONCERTED ACTIONS OF AZIRIDINE AND QUINONE MOIETIES OF DIAZIQUONE, Chemical research in toxicology, 11(4), 1998, pp. 360-368
The biologic functions attributed to the nucleophosphoprotein p53 have
been increasing in recent years. Some studies suggested that wild typ
e p53 is responsible for cell cycle arrest brought about as a response
to exposure of mammalian cells to DNA-damaging agents. This cell cycl
e arrest occurs in order for cells to repair the damaged macromolecule
s. Extensively damaged cells are also thought to undergo apoptosis via
the p53-dependent or -independent signal transduction pathways. In th
is study, we investigated the ability of diaziridinylbenzoquinones to
increase p53 levels in the human breast cancer cell line MCF-7. Diaziq
uone (AZQ), an anticancer agent, and its derivatives, diaziridinequino
ne (DZQ) and methyldiaziridinequinone (MeDZQ), induced p53 in a dose-a
nd time-dependent manner as measured by the electrophoretic mobility s
hift assay. Wild type p53 induction by AZQ was suppressed when DT-diap
horase activity was inhibited by pretreating the cells with dicumarol.
Aside from their potent alkylating activity, these agents also underg
o redox cycling as evidenced by oxygen consumption and the production
of reactive oxygen species (ROS). Inhibition of ROS production by the
antioxidant enzyme catalase reduced AZQ- and DZQ-mediated p53 inductio
n by about 45%. Thiotepa, a non-quinone aziridine-containing agent, an
d 1,4-benzoquinone (p-BQ), a redox cycling quinone, increased p53 leve
ls. The nonalkylator oxygen-radical-generating agent menadione (MD) ca
used p53 induction only when MCF-7 cells were allowed to recover in dr
ug-free media. On the basis of these data, we propose that the bioredu
ctive activation of AZQ is a prerequisite for p53 induction. Moreover,
the induction of p53 by AZQ requires both the quinone and the aziridi
ne moieties of the AZQ molecule. Although AZQ and its analogues increa
sed p53 levels in MCF-7 cells, p53 induction in these cells may not be
responsible for the apoptosis seen upon treatment of MCF-7 cells with
these agents. The uncoupling of p53 induction and apoptosis is eviden
ced by the generation of nucleosomal DNA laddering in aziridinequinone
-treated T47D cells, a breast cancer cell line bearing a p53 mutation.